Publication

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

GLIMP Investigators, Di Pasquale, M. F., Sotgiu, G., Gramegna, A., Radovanovic, D., Terraneo, S., Reyes, L. F., Rupp, J., del Castillo, J. G., Blasi, F., Aliberti, S. & Restrepo, M. I., 1-May-2019, In : Clinical Infectious Diseases. 68, 9, p. 1482-1493 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

GLIMP Investigators, Di Pasquale, M. F., Sotgiu, G., Gramegna, A., Radovanovic, D., Terraneo, S., ... Restrepo, M. I. (2019). Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clinical Infectious Diseases, 68(9), 1482-1493. https://doi.org/10.1093/cid/ciy723

Author

GLIMP Investigators ; Di Pasquale, Marta Francesca ; Sotgiu, Giovanni ; Gramegna, Andrea ; Radovanovic, Dejan ; Terraneo, Silvia ; Reyes, Luis F. ; Rupp, Jan ; del Castillo, Juan Gonzalez ; Blasi, Francesco ; Aliberti, Stefano ; Restrepo, Marcos I. / Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. In: Clinical Infectious Diseases. 2019 ; Vol. 68, No. 9. pp. 1482-1493.

Harvard

GLIMP Investigators, Di Pasquale, MF, Sotgiu, G, Gramegna, A, Radovanovic, D, Terraneo, S, Reyes, LF, Rupp, J, del Castillo, JG, Blasi, F, Aliberti, S & Restrepo, MI 2019, 'Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients', Clinical Infectious Diseases, vol. 68, no. 9, pp. 1482-1493. https://doi.org/10.1093/cid/ciy723

Standard

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. / GLIMP Investigators; Di Pasquale, Marta Francesca; Sotgiu, Giovanni; Gramegna, Andrea; Radovanovic, Dejan; Terraneo, Silvia; Reyes, Luis F.; Rupp, Jan; del Castillo, Juan Gonzalez; Blasi, Francesco; Aliberti, Stefano; Restrepo, Marcos I.

In: Clinical Infectious Diseases, Vol. 68, No. 9, 01.05.2019, p. 1482-1493.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

GLIMP Investigators, Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S et al. Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clinical Infectious Diseases. 2019 May 1;68(9):1482-1493. https://doi.org/10.1093/cid/ciy723


BibTeX

@article{1a60063a5da943ada0b49470391d57db,
title = "Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients",
abstract = "Background. The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia.Methods. We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor.Results. At least 1 risk factor for immunocompromise was recorded in 18{\%} of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45{\%}), hematological cancer (25{\%}), and chemotherapy (22{\%}) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non-community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P <.001).Conclusions. Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.",
keywords = "pneumonia, multidrug-resistant pathogens, microbiology, MRSA, immunocompromise, BLOOD-STREAM INFECTIONS, MULTIDRUG-RESISTANT PATHOGENS, RESPIRATORY-TRACT INFECTIONS, RISK-FACTORS, PNEUMOCYSTIS PNEUMONIA, TRANSPLANT RECIPIENTS, HOSPITALIZED-PATIENTS, BACTERIAL PNEUMONIA, DISEASES-SOCIETY, MANAGEMENT",
author = "{GLIMP Investigators} and {Di Pasquale}, {Marta Francesca} and Giovanni Sotgiu and Andrea Gramegna and Dejan Radovanovic and Silvia Terraneo and Reyes, {Luis F.} and Jan Rupp and {del Castillo}, {Juan Gonzalez} and Francesco Blasi and Stefano Aliberti and Restrepo, {Marcos I.} and Aruj, {Patricia Karina} and Silvia Attorri and Enrique Barimboim and Caeiro, {Juan Pablo} and Garzon, {Maria I.} and Cambursano, {Victor Hugo} and A. Cazaux and Adrian Ceccato and Julio Chertcoff and Florencia Lascar and {Di Tulio}, Fernando and Diaz, {Ariel Cordon} and {de Vedia}, Lautaro and Ganaha, {Maria Cristina} and Sandra Lambert and Luna, {Carlos M.} and Malberti, {Alessio Gerardo} and Nora Morcillo and Silvina Tartara and Cetrangolo, {Antonio A.} and Claudia Pensotti and Privada Monte and Betiana Pereyra and Scapellato, {Pablo Gustavo} and Stagnaro, {Juan Pablo} and Sonali Shah and Felix Lotsch and Florian Thalhammer and Kurt Anseeuw and Francois, {Camille A.} and {Van Braeckel}, Eva and Vincent, {Jean Louis} and Djimon, {Marcel Zannou} and Jules Bashi and Roger Dodo and Jin-fu Xu and Doina Rusu and Cristina Toma and {van Boven}, {Job F. M.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1093/cid/ciy723",
language = "English",
volume = "68",
pages = "1482--1493",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

AU - GLIMP Investigators

AU - Di Pasquale, Marta Francesca

AU - Sotgiu, Giovanni

AU - Gramegna, Andrea

AU - Radovanovic, Dejan

AU - Terraneo, Silvia

AU - Reyes, Luis F.

AU - Rupp, Jan

AU - del Castillo, Juan Gonzalez

AU - Blasi, Francesco

AU - Aliberti, Stefano

AU - Restrepo, Marcos I.

AU - Aruj, Patricia Karina

AU - Attorri, Silvia

AU - Barimboim, Enrique

AU - Caeiro, Juan Pablo

AU - Garzon, Maria I.

AU - Cambursano, Victor Hugo

AU - Cazaux, A.

AU - Ceccato, Adrian

AU - Chertcoff, Julio

AU - Lascar, Florencia

AU - Di Tulio, Fernando

AU - Diaz, Ariel Cordon

AU - de Vedia, Lautaro

AU - Ganaha, Maria Cristina

AU - Lambert, Sandra

AU - Luna, Carlos M.

AU - Malberti, Alessio Gerardo

AU - Morcillo, Nora

AU - Tartara, Silvina

AU - Cetrangolo, Antonio A.

AU - Pensotti, Claudia

AU - Monte, Privada

AU - Pereyra, Betiana

AU - Scapellato, Pablo Gustavo

AU - Stagnaro, Juan Pablo

AU - Shah, Sonali

AU - Lotsch, Felix

AU - Thalhammer, Florian

AU - Anseeuw, Kurt

AU - Francois, Camille A.

AU - Van Braeckel, Eva

AU - Vincent, Jean Louis

AU - Djimon, Marcel Zannou

AU - Bashi, Jules

AU - Dodo, Roger

AU - Xu, Jin-fu

AU - Rusu, Doina

AU - Toma, Cristina

AU - van Boven, Job F. M.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background. The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia.Methods. We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor.Results. At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non-community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P <.001).Conclusions. Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.

AB - Background. The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia.Methods. We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor.Results. At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non-community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P <.001).Conclusions. Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses.

KW - pneumonia

KW - multidrug-resistant pathogens

KW - microbiology

KW - MRSA

KW - immunocompromise

KW - BLOOD-STREAM INFECTIONS

KW - MULTIDRUG-RESISTANT PATHOGENS

KW - RESPIRATORY-TRACT INFECTIONS

KW - RISK-FACTORS

KW - PNEUMOCYSTIS PNEUMONIA

KW - TRANSPLANT RECIPIENTS

KW - HOSPITALIZED-PATIENTS

KW - BACTERIAL PNEUMONIA

KW - DISEASES-SOCIETY

KW - MANAGEMENT

U2 - 10.1093/cid/ciy723

DO - 10.1093/cid/ciy723

M3 - Article

VL - 68

SP - 1482

EP - 1493

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 9

ER -

ID: 96791038